Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 16Active not recruiting 5Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk 1

Interventions

pembrolizumab 20Magnetic Resonance Spectroscopy 13Specimen Handling 12Cyclophosphamide 11fludarabine 10Radiotherapy 9Biopsy 9atezolizumab 7Nivolumab 7Radiation 6Gemcitabine 5fludarabine phosphate 4aldesleukin 4Prednisone 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4ALT-803 4lenvatinib 3avelumab 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3Paclitaxel 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × pegylated granulocyte colony-stimulating factor × 1 year × Clear all
NCT06254742 2025-08-07

A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Withdrawn
Classical hematology

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk

Data powered by HemOnc (CC BY 4.0) Colophon âš¡